Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic cultured keratinocytes and fibroblasts - Organogenesis

Drug Profile

Allogeneic cultured keratinocytes and fibroblasts - Organogenesis

Alternative Names: Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen; Gintuit

Latest Information Update: 14 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Organogenesis
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Gingival disorders
  • Discontinued Alveolar bone loss

Most Recent Events

  • 10 Dec 2018 As part of merger, Organogenesis became a subsidiary of Organogenesis Holdings (formerly Avista Healthcare Public)
  • 10 Dec 2013 Organogenesis completes enrolment in its phase I/II trial for Gingival disorders & Alveolar bone loss following tooth extraction in the USA (NCT01929954)
  • 31 Jul 2013 Phase-I/II clinical trials in Alveolar bone loss in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top